

Title (en)

COMBINATIONS OF THE BTK INHIBITOR GS-4059 WITH INHIBITORS SELECTED FROM A JAK, ASK1, BRD AND/OR MMP9 INHIBITOR TO TREAT CANCER, ALLERGIC DISORDERS, AUTOIMMUNE DISEASES OR INFLAMMATORY DISEASES

Title (de)

KOMBINATIONEN DER BTK-INHIBITOREN GS-4059 MIT EINEM AUSGEWÄHLTEN JAK-, ASK1-, BRD- UND/ODER MMP9-INHIBITOR ZUR BEHANDLUNG VON KREBS, ALLERGISCHEN ERKRANKUNGEN, AUTOIMMUNERKRANKUNGEN ODER ENTZÜNDLICHEN ERKRANKUNGEN

Title (fr)

COMBINAISONS DE L'INHIBITEUR DE BTK GS-4059 AVEC DES INHIBITEURS CHOISIS PARMI UN INHIBITEUR DE JAK, D'ASK1, DE BRD ET/OU DE MMP9 POUR TRAITER LE CANCER, LES TROUBLES ALLERGIQUES, LES MALADIES AUTO-IMMUNES OU LES MALADIES INFLAMMATOIRES

Publication

**EP 3355871 A1 20180808 (EN)**

Application

**EP 16785022 A 20160930**

Priority

- US 201562236409 P 20151002
- US 201562236729 P 20151002
- US 201562236741 P 20151002
- US 201562236345 P 20151002
- US 2016054780 W 20160930

Abstract (en)

[origin: WO2017059252A1] Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, and allergic, autoimmune, and inflammatory disorders including hematological malignancies. In particular, the methods include administration of a BTK inhibitor and with one or more inhibitor. For example, the one or more inhibitor may be a JAK inhibitor, a ASK1 inhibitor, a BRD4 inhibitor or an MMP9 inhibitor.

IPC 8 full level

**A61K 31/00** (2006.01); **A61K 31/437** (2006.01); **A61K 31/4545** (2006.01); **A61K 31/506** (2006.01); **A61K 31/519** (2006.01); **A61K 31/522** (2006.01); **A61K 31/5375** (2006.01); **A61K 31/541** (2006.01); **A61K 31/553** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)

**A61K 31/00** (2013.01); **A61K 31/437** (2013.01); **A61K 31/4545** (2013.01); **A61K 31/506** (2013.01); **A61K 31/519** (2013.01); **A61K 31/522** (2013.01); **A61K 31/5375** (2013.01); **A61K 31/541** (2013.01); **A61K 31/553** (2013.01); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 11/14** (2017.12); **A61P 17/02** (2017.12); **A61P 19/02** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/02** (2017.12); **A61P 37/06** (2017.12); **A61P 37/08** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 2017059252A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2017059252 A1 20170406**; AU 2016329075 A1 20180426; CA 3000746 A1 20170406; EP 3355871 A1 20180808; HK 1258762 A1 20191122; JP 2018534263 A 20181122; JP 2021014466 A 20210212; TW 201726130 A 20170801

DOCDB simple family (application)

**US 2016054780 W 20160930**; AU 2016329075 A 20160930; CA 3000746 A 20160930; EP 16785022 A 20160930; HK 19101080 A 20190122; JP 2018516487 A 20160930; JP 2020187956 A 20201111; TW 105131809 A 20160930